Should Aripiprazole (Abilify) Be Tapered Rather Than Stopped Abruptly?
Yes, aripiprazole should generally be tapered gradually rather than stopped abruptly to minimize withdrawal effects and prevent symptom exacerbation, though the FDA label does not mandate tapering and the evidence is mixed.
Evidence from FDA Labeling
The FDA prescribing information for Abilify 1 does not explicitly require tapering when discontinuing aripiprazole. The label discusses switching strategies between antipsychotics, noting that "while immediate discontinuation of the previous antipsychotic treatment may be acceptable for some patients with schizophrenia, more gradual discontinuation may be most appropriate for others" 1. However, this guidance pertains to switching between antipsychotics rather than complete discontinuation.
Guideline Evidence on Antipsychotic Discontinuation
The most recent and relevant guideline evidence supports gradual tapering of antipsychotics. The 2021 Mayo Clinic polypharmacy guidelines 2 explicitly recommend that "when considering deprescribing of antipsychotics, a gradual withdrawal strategy is recommended to minimize potential discontinuation effects." The guidelines warn that "abrupt discontinuation has associated difficulties including dyskinesias, parkinsonian symptoms, dystonias, and neuroleptic malignant syndrome" 2. Withdrawal should be gradual, in most cases extending over a period of greater than 1 month 2.
The 2025 INTEGRATE schizophrenia guidelines 3 emphasize that "antipsychotic switching should involve gradual cross-titration informed by the half-life and receptor profile of each medication," though this specifically addresses switching rather than complete discontinuation.
Research Evidence on Aripiprazole-Specific Tapering
The research evidence specifically examining aripiprazole discontinuation strategies shows:
A 2009 randomized study 4 found that patients switched to aripiprazole with immediate discontinuation of their previous antipsychotic showed an increase in symptom severity at week 1, suggesting that abrupt changes can cause early worsening. The authors concluded that "previous treatment's tapering off strategy for switching patients to aripiprazole could be preferable as compared to abrupt discontinuation, in order to prevent early worsening of symptoms and premature discontinuation of treatment."
A 2003 multicenter study 5 comparing three switching strategies found that "any of the three strategies evaluated can be used safely for switching patients to aripiprazole," including immediate discontinuation, though this addressed switching between antipsychotics rather than complete cessation.
A 2012 review 6 noted that "despite the lack of evidence, experts recommend an overlap strategy" when transitioning between antipsychotics.
Broader Context: Antipsychotic Withdrawal Risks
Recent evidence on antipsychotic discontinuation more broadly 7, 8 highlights important considerations:
- Relapse after abrupt cessation is common, often within 3 months, possibly due to dopaminergic supersensitivity 7
- Hyperbolic tapering, with slow and progressively smaller dose reductions, may reduce withdrawal effects and relapse risk 7
- Withdrawal symptoms may include dyskinesias, parkinsonian symptoms, dystonias, and in rare cases neuroleptic malignant syndrome 2
Practical Tapering Approach
Based on the available evidence, here is a structured approach:
When Tapering Is Most Important:
- Long-term use (months to years of treatment)
- Higher doses of aripiprazole
- History of withdrawal symptoms with previous medication changes
- Patients with sustained remission who are attempting complete discontinuation
Recommended Tapering Strategy:
Duration: Taper over at least 1 month, though longer periods (several months) may be appropriate for patients on long-term therapy 2
Dose Reduction Pattern: Consider hyperbolic tapering with progressively smaller reductions:
- Example: 15 mg → 10 mg (2 weeks) → 7.5 mg (2 weeks) → 5 mg (2-4 weeks) → 2.5 mg (2-4 weeks) → stop
- For patients at higher risk, extend intervals and use smaller decrements
Monitoring: Assess every 2-4 weeks during tapering for:
- Withdrawal symptoms (akathisia, insomnia, agitation, nausea)
- Return of psychotic symptoms
- Extrapyramidal symptoms
- Mood changes
Be prepared to pause or reverse the taper if significant symptoms emerge 2
Important Caveats
- The evidence specifically for aripiprazole tapering is limited, with most studies examining switching strategies rather than complete discontinuation
- Aripiprazole has a long half-life (75 hours for the active metabolite), which may provide some natural buffering against abrupt withdrawal compared to shorter-acting antipsychotics
- Some patients may tolerate more rapid discontinuation, particularly those on short-term therapy or lower doses
- The risk-benefit calculation differs based on indication (schizophrenia vs. bipolar disorder vs. adjunctive depression treatment)
In clinical practice, err on the side of gradual tapering to minimize the risk of withdrawal symptoms, symptom exacerbation, and treatment discontinuation, even though abrupt cessation may be tolerated by some patients.